Many With Relapsed/Refractory Lymphoma in Pregnancy Delay Treatment
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
TUESDAY, June 6, 2023 -- Most women with relapsed/refractory lymphoma during pregnancy defer therapy and there are few obstetric or neonatal complications, according to a study published online June 1 in Blood Advances.
Faheem Farooq, M.D., from Rutgers Cancer Institute of New Jersey in New Brunswick, and colleagues conducted a retrospective analysis across 10 international centers involving 23 patients with relapsed/refractory lymphoma during pregnancy. Of the patients, 18 had classic Hodgkin lymphoma, two had peripheral T-cell lymphoma, and one each had diffuse large B-cell, follicular, and marginal zone lymphoma.
The researchers found that most patients chose to delay therapy until postpartum while under close surveillance, while five of the patients received intentional antenatal therapy at a median of 26 weeks of gestation; one of these received checkpoint inhibitor therapy. Nineteen live births occurred; most were born via vaginal delivery. More than half of the births were preterm (median gestation, 36 weeks), with most initiated by clinicians. The median birthweight was 2,777 g; no malformations or genetic diseases were identified. Nine patients underwent transplant postpartum. Three-year progression-free and overall survival were 24 and 83 percent, respectively, with median follow-up of 37 months.
"The goal of this study is to provide data that can inform patients and providers," a coauthor said in a statement. "While a relapsed/refractory lymphoma diagnosis during pregnancy is rare, we hope to ensure that oncologists and women have some form of guidance on how to approach this complex clinical scenario."
Several authors disclosed ties to the pharmaceutical and biotechnology industries.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted June 2023
Read this next
About 56 Percent of Pregnant Smokers Quit During Pregnancy
THURSDAY, May 2, 2024 -- More than half of women who smoke before pregnancy quit while pregnant, according to research published in the May 2 issue of the U.S. Centers for Disease...
CDC: Decrease in Maternal Mortality Rates Seen in 2022
THURSDAY, May 2, 2024 -- In 2022, there was a decrease in maternal mortality rates, according to a report published in the May Health E-Stats, a publication of the U.S. Centers...
Antenatal Corticosteroids Do Not Negatively Impact Offspring
FRIDAY, April 26, 2024 -- Administration of antenatal corticosteroids to persons at risk for late preterm delivery is not associated with adverse childhood neurodevelopmental...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.